Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antitubercular Agents | 9 | 2020 | 28 | 2.030 |
Why?
|
| Anti-Bacterial Agents | 6 | 2023 | 352 | 1.750 |
Why?
|
| Macrocyclic Compounds | 3 | 2022 | 12 | 1.720 |
Why?
|
| Peptides, Cyclic | 2 | 2020 | 29 | 1.330 |
Why?
|
| Urea | 3 | 2023 | 41 | 1.280 |
Why?
|
| Carbolines | 3 | 2018 | 15 | 1.170 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 75 | 1.160 |
Why?
|
| Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) | 1 | 2023 | 1 | 0.910 |
Why?
|
| Mycobacterium tuberculosis | 10 | 2020 | 90 | 0.880 |
Why?
|
| Education, Pharmacy | 1 | 2023 | 43 | 0.840 |
Why?
|
| Pharmacy | 1 | 2023 | 30 | 0.830 |
Why?
|
| Structure-Activity Relationship | 11 | 2023 | 409 | 0.790 |
Why?
|
| Bacteria | 2 | 2016 | 255 | 0.790 |
Why?
|
| Indoles | 3 | 2018 | 158 | 0.620 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 803 | 0.610 |
Why?
|
| Molecular Structure | 8 | 2020 | 492 | 0.590 |
Why?
|
| Oxazines | 1 | 2016 | 26 | 0.570 |
Why?
|
| NF-kappa B | 4 | 2014 | 339 | 0.480 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 7 | 0.470 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 433 | 0.460 |
Why?
|
| Diarylheptanoids | 1 | 2013 | 1 | 0.450 |
Why?
|
| Nitric Oxide Synthase | 1 | 2012 | 128 | 0.410 |
Why?
|
| Stilbenes | 1 | 2012 | 44 | 0.410 |
Why?
|
| Flavonoids | 1 | 2012 | 87 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 149 | 0.380 |
Why?
|
| Peptide Library | 2 | 2007 | 25 | 0.380 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2018 | 83 | 0.370 |
Why?
|
| Ribonucleotide Reductases | 1 | 2009 | 8 | 0.350 |
Why?
|
| Deoxyadenosines | 1 | 2009 | 9 | 0.350 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2020 | 201 | 0.330 |
Why?
|
| Piperidines | 1 | 2009 | 77 | 0.330 |
Why?
|
| Adenosine Triphosphate | 1 | 2009 | 196 | 0.320 |
Why?
|
| Small Molecule Libraries | 4 | 2013 | 45 | 0.320 |
Why?
|
| Uridine | 1 | 2007 | 6 | 0.310 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2007 | 11 | 0.300 |
Why?
|
| Thymine | 1 | 2007 | 25 | 0.290 |
Why?
|
| Dipeptides | 1 | 2007 | 32 | 0.290 |
Why?
|
| Cyclization | 2 | 2020 | 48 | 0.290 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2018 | 115 | 0.270 |
Why?
|
| Aromatase | 2 | 2018 | 19 | 0.260 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 2 | 2018 | 16 | 0.260 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 289 | 0.250 |
Why?
|
| Bacterial Infections | 2 | 2016 | 43 | 0.240 |
Why?
|
| Academies and Institutes | 1 | 2023 | 37 | 0.220 |
Why?
|
| Drug Design | 3 | 2014 | 162 | 0.210 |
Why?
|
| Microwaves | 1 | 2022 | 24 | 0.210 |
Why?
|
| Escherichia coli | 2 | 2016 | 453 | 0.200 |
Why?
|
| Models, Molecular | 2 | 2016 | 808 | 0.200 |
Why?
|
| Educational Status | 1 | 2023 | 313 | 0.200 |
Why?
|
| Curriculum | 1 | 2023 | 265 | 0.190 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1502 | 0.180 |
Why?
|
| Humans | 11 | 2023 | 37093 | 0.170 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 2231 | 0.160 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 15 | 0.160 |
Why?
|
| Chemoprevention | 1 | 2018 | 35 | 0.160 |
Why?
|
| Biological Availability | 1 | 2018 | 88 | 0.160 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2018 | 71 | 0.160 |
Why?
|
| Animals | 9 | 2018 | 15081 | 0.160 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2016 | 8 | 0.140 |
Why?
|
| Bacillus subtilis | 1 | 2016 | 16 | 0.140 |
Why?
|
| Halogenation | 1 | 2016 | 19 | 0.140 |
Why?
|
| Cell Line | 4 | 2012 | 1354 | 0.140 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 41 | 0.140 |
Why?
|
| Vero Cells | 3 | 2012 | 93 | 0.130 |
Why?
|
| Mice | 6 | 2018 | 5913 | 0.130 |
Why?
|
| Amides | 2 | 2014 | 68 | 0.130 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2016 | 107 | 0.130 |
Why?
|
| Spectinomycin | 1 | 2014 | 2 | 0.120 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2014 | 5 | 0.120 |
Why?
|
| Streptomyces | 1 | 2014 | 16 | 0.120 |
Why?
|
| Purine Nucleosides | 1 | 2014 | 14 | 0.120 |
Why?
|
| Hydrogenation | 1 | 2013 | 1 | 0.110 |
Why?
|
| Amination | 1 | 2013 | 5 | 0.110 |
Why?
|
| Chromatography | 1 | 2013 | 16 | 0.110 |
Why?
|
| Oximes | 1 | 2013 | 6 | 0.110 |
Why?
|
| Isomerism | 1 | 2013 | 63 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 356 | 0.110 |
Why?
|
| Amines | 1 | 2013 | 39 | 0.110 |
Why?
|
| Leishmaniasis | 1 | 2012 | 6 | 0.110 |
Why?
|
| Nitric Oxide | 2 | 2013 | 316 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 112 | 0.110 |
Why?
|
| Leishmania donovani | 1 | 2012 | 17 | 0.110 |
Why?
|
| Trypanocidal Agents | 1 | 2012 | 39 | 0.100 |
Why?
|
| Cell Survival | 2 | 2012 | 864 | 0.100 |
Why?
|
| Receptors, Eph Family | 1 | 2011 | 4 | 0.100 |
Why?
|
| Epoxide Hydrolases | 1 | 2011 | 7 | 0.100 |
Why?
|
| Stereoisomerism | 2 | 2011 | 167 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 132 | 0.090 |
Why?
|
| Carbohydrate Epimerases | 1 | 2009 | 1 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2009 | 36 | 0.090 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2009 | 9 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2011 | 1198 | 0.080 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 265 | 0.080 |
Why?
|
| Oxazoles | 1 | 2008 | 19 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2009 | 82 | 0.080 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2009 | 206 | 0.080 |
Why?
|
| Isoxazoles | 1 | 2007 | 11 | 0.080 |
Why?
|
| Silanes | 1 | 2007 | 5 | 0.070 |
Why?
|
| Polystyrenes | 1 | 2007 | 19 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1039 | 0.040 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 2 | 0.030 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Ribosomes | 1 | 2014 | 32 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 41 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 30 | 0.030 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 84 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 95 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 77 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 103 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 83 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 136 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 220 | 0.030 |
Why?
|
| Female | 1 | 2011 | 20969 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 269 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2013 | 859 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 928 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 439 | 0.020 |
Why?
|
| Tenuazonic Acid | 1 | 2009 | 1 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 2009 | 7 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2009 | 109 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2009 | 65 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 540 | 0.020 |
Why?
|
| Aorta | 1 | 2009 | 167 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2009 | 207 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 426 | 0.020 |
Why?
|
| Nitrofurans | 1 | 2007 | 1 | 0.020 |
Why?
|
| Furans | 1 | 2008 | 38 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2009 | 272 | 0.020 |
Why?
|
| Biofilms | 1 | 2009 | 168 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2009 | 362 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2009 | 308 | 0.020 |
Why?
|
| Rats | 1 | 2007 | 3483 | 0.010 |
Why?
|
| Male | 1 | 2009 | 20025 | 0.010 |
Why?
|